Literature DB >> 32725330

Hypoxia and perfusion in breast cancer: simultaneous assessment using PET/MR imaging.

Julia C Carmona-Bozo1, Roido Manavaki1, Ramona Woitek1,2, Turid Torheim3, Gabrielle C Baxter1, Corradina Caracò1, Elena Provenzano3,4, Martin J Graves1,5, Tim D Fryer6, Andrew J Patterson1,5, Fiona J Gilbert7.   

Abstract

OBJECTIVES: Hypoxia is associated with poor prognosis and treatment resistance in breast cancer. However, the temporally variant nature of hypoxia can complicate interpretation of imaging findings. We explored the relationship between hypoxia and vascular function in breast tumours through combined 18F-fluoromisonidazole (18 F-FMISO) PET/MRI, with simultaneous assessment circumventing the effect of temporal variation in hypoxia and perfusion.
METHODS: Women with histologically confirmed, primary breast cancer underwent a simultaneous 18F-FMISO-PET/MR examination. Tumour hypoxia was assessed using influx rate constant Ki and hypoxic fractions (%HF), while parameters of vascular function (Ktrans, kep, ve, vp) and cellularity (ADC) were derived from dynamic contrast-enhanced (DCE) and diffusion-weighted (DW)-MRI, respectively. Additional correlates included histological subtype, grade and size. Relationships between imaging variables were assessed using Pearson correlation (r).
RESULTS: Twenty-nine women with 32 lesions were assessed. Hypoxic fractions > 1% were observed in 6/32 (19%) cancers, while 18/32 (56%) tumours showed a %HF of zero. The presence of hypoxia in lesions was independent of histological subtype or grade. Mean tumour Ktrans correlated negatively with Ki (r = - 0.38, p = 0.04) and %HF (r = - 0.33, p = 0.04), though parametric maps exhibited intratumoural heterogeneity with hypoxic regions colocalising with both hypo- and hyperperfused areas. No correlation was observed between ADC and DCE-MRI or PET parameters. %HF correlated positively with lesion size (r = 0.63, p = 0.001).
CONCLUSION: Hypoxia measured by 18F-FMISO-PET correlated negatively with Ktrans from DCE-MRI, supporting the hypothesis of perfusion-driven hypoxia in breast cancer. Intratumoural hypoxia-perfusion relationships were heterogeneous, suggesting that combined assessment may be needed for disease characterisation, which could be achieved using simultaneous multimodality imaging. KEY POINTS: • At the tumour level, hypoxia measured by 18F-FMISO-PET was negatively correlated with perfusion measured by DCE-MRI, which supports the hypothesis of perfusion-driven hypoxia in breast cancer. • No associations were observed between 18F-FMISO-PET parameters and tumour histology or grade, but tumour hypoxic fractions increased with lesion size. • Intratumoural hypoxia-perfusion relationships were heterogeneous, suggesting that the combined hypoxia-perfusion status of tumours may need to be considered for disease characterisation, which can be achieved via simultaneous multimodality imaging as reported here.

Entities:  

Keywords:  Breast cancer; Hypoxia; PET/MRI; Perfusion

Mesh:

Year:  2020        PMID: 32725330      PMCID: PMC7755870          DOI: 10.1007/s00330-020-07067-2

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  58 in total

1.  Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer.

Authors:  Daniele Generali; Alfredo Berruti; Maria P Brizzi; Leticia Campo; Simone Bonardi; Simon Wigfield; Alessandra Bersiga; Giovanni Allevi; Manuela Milani; Sergio Aguggini; Valeria Gandolfi; Luigi Dogliotti; Alberto Bottini; Adrian L Harris; Stephen B Fox
Journal:  Clin Cancer Res       Date:  2006-08-01       Impact factor: 12.531

2.  Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ.

Authors:  Karolina Helczynska; Asa Kronblad; Annika Jögi; Elise Nilsson; Siv Beckman; Göran Landberg; Sven Påhlman
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

3.  Tumor oxygenation correlates with molecular growth determinants in breast cancer.

Authors:  P Hohenberger; C Felgner; W Haensch; P M Schlag
Journal:  Breast Cancer Res Treat       Date:  1998-03       Impact factor: 4.872

4.  Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma.

Authors:  H Kimura; R D Braun; E T Ong; R Hsu; T W Secomb; D Papahadjopoulos; K Hong; M W Dewhirst
Journal:  Cancer Res       Date:  1996-12-01       Impact factor: 12.701

Review 5.  The hypoxic tumor microenvironment: A driving force for breast cancer progression.

Authors:  Gregg L Semenza
Journal:  Biochim Biophys Acta       Date:  2015-06-14

6.  Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements.

Authors:  P Vaupel; K Schlenger; C Knoop; M Höckel
Journal:  Cancer Res       Date:  1991-06-15       Impact factor: 12.701

7.  Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma.

Authors:  S K Chia; C C Wykoff; P H Watson; C Han; R D Leek; J Pastorek; K C Gatter; P Ratcliffe; A L Harris
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

8.  Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma.

Authors:  Charlton Cooper; Guang-Yu Liu; Yu-Lian Niu; Sylvia Santos; Leigh C Murphy; Peter H Watson
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

Review 9.  Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response.

Authors:  Mark W Dewhirst; Yiting Cao; Benjamin Moeller
Journal:  Nat Rev Cancer       Date:  2008-06       Impact factor: 60.716

Review 10.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review.

Authors:  P Vaupel; F Kallinowski; P Okunieff
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

View more
  7 in total

1.  The optimal 18F-fluoromisonidazole PET threshold to define tumor hypoxia in preclinical squamous cell carcinomas using pO2 electron paramagnetic resonance imaging as reference truth.

Authors:  Inna Gertsenshteyn; Boris Epel; Amandeep Ahluwalia; Heejong Kim; Xiaobing Fan; Eugene Barth; Marta Zamora; Erica Markiewicz; Hsiu-Ming Tsai; Subramanian Sundramoorthy; Lara Leoni; John Lukens; Mohammed Bhuiyan; Richard Freifelder; Anna Kucharski; Mihai Giurcanu; Brian B Roman; Gregory Karczmar; Chien-Min Kao; Howard Halpern; Chin-Tu Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-07-06       Impact factor: 10.057

Review 2.  Integrating mechanism-based modeling with biomedical imaging to build practical digital twins for clinical oncology.

Authors:  Chengyue Wu; Guillermo Lorenzo; David A Hormuth; Ernesto A B F Lima; Kalina P Slavkova; Julie C DiCarlo; John Virostko; Caleb M Phillips; Debra Patt; Caroline Chung; Thomas E Yankeelov
Journal:  Biophys Rev (Melville)       Date:  2022-05-17

Review 3.  Hypoxia Imaging As a Guide for Hypoxia-Modulated and Hypoxia-Activated Therapy.

Authors:  Jeffrey R Brender; Yu Saida; Nallathamby Devasahayam; Murali C Krishna; Shun Kishimoto
Journal:  Antioxid Redox Signal       Date:  2022-01       Impact factor: 8.401

Review 4.  Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies.

Authors:  Raefa Abou Khouzam; Klaudia Brodaczewska; Aleksandra Filipiak; Nagwa Ahmed Zeinelabdin; Stephanie Buart; Cezary Szczylik; Claudine Kieda; Salem Chouaib
Journal:  Front Immunol       Date:  2021-01-20       Impact factor: 7.561

Review 5.  The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia.

Authors:  Bernard Gallez
Journal:  Front Pharmacol       Date:  2022-07-15       Impact factor: 5.988

6.  Optimal treatment occasion for ultrasound stimulated microbubbles in promoting gemcitabine delivery to VX2 tumors.

Authors:  Tingting Luo; Luhua Bai; Yi Zhang; Leidan Huang; Hui Li; Shunji Gao; Xiaoxiao Dong; Ningshan Li; Zheng Liu
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

7.  68Ga-FAPI-04 Versus 18F-FDG PET/CT in the Detection of Hepatocellular Carcinoma.

Authors:  Hao Wang; Wenwei Zhu; Shuhua Ren; Yanyan Kong; Qi Huang; Jun Zhao; Yihui Guan; Huliang Jia; Jinhong Chen; Lu Lu; Fang Xie; Lunxiu Qin
Journal:  Front Oncol       Date:  2021-06-25       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.